Brimonidine Purite 0.15% Versus Dorzolamide 2% Used as Adjunctive Therapy to Latanoprost

Inclusion criteria

• · Male or female > 18 years of age

• Diagnosis of open-angle glaucoma or ocular hypertension
• IOP > 16 mm Hg in each eye at the latanoprost -treated baseline evaluation
• Presently on latanoprost monotherapy for at least 6 weeks
• Ability to provide informed consent and likely to complete all study visits

Exclusion criteria

• · Known contraindication or allergy to brimonidine or any of its components

• Subjects must be naive to brimonidine 0.2% or brimonidine Purite 0.15% and dorzolamide 2%
• Uncontrolled systemic disease
• Active ocular disease other than glaucoma or ocular hypertension (e.g. uveitis, ocular infections, or severe dry eye). Patients with chronic mild blepharitis, cataract, age-related macular degeneration, or background diabetic retinopathy may be enrolled at the discretion of the investigator.
• Required use of ocular medications other than the study medications during the study (intermittent use of artificial tear product is allowed).
• Corneal abnormalities
• History of intraocular surgery within the last 3 months
• Female patients of childbearing potential who are pregnant, lactating, planning a pregnancy, or not using a reliable form of birth control
• Visual field loss, which in the opinion of the investigator, is functionally significant, or evidence of progressive visual field loss within the last year.